Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 17/20 | 0.62 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.56 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.56 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.56 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080011 | 0.91 | PLA2G1B (0.68) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL8028750 | 0.89 | PLA2G1B (0.71) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL8029834 | 0.87 | PLA2G1B (0.62) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL9081427 | 0.87 | PLA2G1B (0.57) | PLA2G1BPLA2G2APLA2G2EPLA2G5 | |
| SCHEMBL9081178 | 0.86 | PLA2G1B (0.57) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL9080332 | 0.84 | PLA2G2A (0.52) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL9082363 | 0.82 | PLA2G1B (0.57) | PLA2G1BPLA2G2A | |
| SCHEMBL8325195 | 0.82 | PLA2G1B (0.88) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL8025842 | 0.81 | PLA2G1B (0.64) | PLA2G1BPLA2G2APLA2G2EPLA2G5 | |
| SCHEMBL7017215 | 0.81 | PLA2G1B (0.83) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |